(Boehringer Ingelheim) – Mary is a tireless advocate who engages with external stakeholders to demonstrate the value of our business to patients and policymakers. This includes Mary’s election to the Pharmaceutical Product Stewardship Working Group Board of Directors, focused on implementation of drug take-back programs.